AMGN Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$281.70 |
| 52 Week High | US$319.60 |
| 52 Week Low | US$240.40 |
| Beta | 0.60 |
| 11 Month Change | -4.00% |
| 3 Month Change | -3.69% |
| 1 Year Change | 15.83% |
| 33 Year Change | 58.10% |
| 5 Year Change | 32.22% |
| Change since IPO | 106.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMGN | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 0.4% | 2.9% | -0.3% |
| 1Y | 15.8% | 5.3% | 2.5% |
Return vs Industry: AMGN exceeded the Austrian Biotechs industry which returned 5.3% over the past year.
Return vs Market: AMGN exceeded the Austrian Market which returned 2.5% over the past year.
Price Volatility
| AMGN volatility | |
|---|---|
| AMGN Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.6% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: AMGN has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: AMGN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
| AMGN fundamental statistics | |
|---|---|
| Market cap | €152.03b |
| Earnings (TTM) | €4.06b |
| Revenue (TTM) | €31.24b |
37.4x
P/E Ratio4.9x
P/S RatioIs AMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGN income statement (TTM) | |
|---|---|
| Revenue | US$32.53b |
| Cost of Revenue | US$12.82b |
| Gross Profit | US$19.71b |
| Other Expenses | US$15.48b |
| Earnings | US$4.23b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.87 |
| Gross Margin | 60.59% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 802.4% |
How did AMGN perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield113%
Payout RatioDoes AMGN pay a reliable dividends?
See AMGN dividend history and benchmarks| Amgen dividend dates | |
|---|---|
| Ex Dividend Date | Nov 18 2024 |
| Dividend Pay Date | Dec 09 2024 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 14 days |
Does AMGN pay a reliable dividends?
See AMGN dividend history and benchmarks